Access
To read this story in full you will need to login or make a payment (see right).
Technology Feature
Nature 431, 599-605 (30 September 2004) | doi:10.1038/431599a; Published online 29 September 2004
RNA interference: The silent treatment
Julie Clayton1
Abstract
Biotech firms are vying to harness the potential of RNA interference. But will its impact be in finding new disease targets, or in RNA-based drugs? Julie Clayton investigates.
The hype surrounding RNA interference (RNAi) 'gene-silencing' technology has both academic labs and biotech companies firmly in its grip. RNAi is lauded as a powerful approach to gene control, with the promise of revolutionizing basic research and providing treatments for intractable conditions such as cancer and neurodegenerative disease.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.